Simpler Grants.gov #RFA-MH-27-135

NIMH Funding Opportunity for Research on Clinical Trials of Rapid-Acting Psychotropic Drugs

This opportunity from the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), seeks research proposals focused on clinical trials of rapid-acting psychotropic interventional drugs (RAPIDs). - Government Buyer: - National Institutes of Health (NIH) - National Institute of Mental Health (NIMH) - OEMs and Key Substances: - 5-HT2A agonists (e.g., psilocybin) - Dissociative anesthetics (e.g., ketamine) - Entactogens (e.g., MDMA) - Products/Services Requested: - Research grant applications addressing methodological challenges in clinical trials of RAPIDs - No specific products, part numbers, or purchase quantities are requested - Unique or Notable Requirements: - Focus on improving understanding of therapeutic effects and clinical trial confidence for RAPIDs - Encourages collaborative research and innovative trial design - Applicants should consult with the U.S. Food and Drug Administration (FDA) for regulatory compliance - This is a research funding opportunity, not a procurement of goods or services

Description

The National Institute of Mental Health (NIMH) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research addressing methodological challenges in clinical trials involving rapid-acting psychotropic interventional drugs (RAPIDs). These drugs include 5-HT2A agonists such as psilocybin, dissociative anesthetics such as ketamine, and entactogens such as MDMA, which have shown benefits for mental health disorders like depression and anxiety. The goal is to improve understanding of therapeutic effects and increase confidence in clinical trial results. Applications are not currently being solicited; this notice allows potential applicants time to prepare collaborations and projects.

View original listing